Back to top
more

Globus Medical (GMED)

(Real Time Quote from BATS)

$56.78 USD

56.78
155,706

+0.56 (1.00%)

Updated Sep 18, 2025 10:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Zacks Equity Research

Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.

Zacks Equity Research

Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D

by Zacks Equity Research

Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.

Zacks Equity Research

Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note

by Zacks Equity Research

QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.

Zacks Equity Research

AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.

Zacks Equity Research

Catalent (CTLT) Expands Its Facility Capabilities in Germany

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Zacks Equity Research

Integra's (IART) New Site to Produce Recalled Tissue Products

by Zacks Equity Research

Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.

Zacks Equity Research

Should You Keep Chemed (CHE) Stock in Your Portfolio Now?

by Zacks Equity Research

Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.

Zacks Equity Research

Here's Why Globus Medical (GMED) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Globus Medical, Inc. (GMED) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

GMED vs. SONVY: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMED vs. SONVY: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why Globus Medical (GMED) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Globus Medical (GMED) Up 7.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why Globus Medical (GMED) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Globus Medical (GMED) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.

Zacks Equity Research

Here's Why Globus Medical (GMED) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

GMED or PEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMED vs. PEN: Which Stock Is the Better Value Option?

Zacks Equity Research

Globus Medical, Inc. (GMED) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Why Globus Medical (GMED) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.